Close Menu

Shield Diagnostics: David Esposito

Sep 06, 2019

David Esposito has been appointed to the board of directors of Shield Diagnostics, a San Jose, California-based rapid molecular diagnostics firm developing assays for resistance-guided therapy. Esposito is currently CEO of ONL Therapeutics. He formerly served as CEO of Armune BioScience, a company that was sold to Exact Sciences in 2017, and he also served as President of Phadia US, an allergy and autoimmune diagnostics firm, playing a pivotal role in selling the business to Thermo Fisher Scientific in 2011.

More Like This

Feb 21, 2020

LifeOmic: Ed Simcox

Precision medicine software firm LifeOmic has named Ed Simcox as its new chief strategy officer. Simcox joins LifeOmic from the US Department of Health and Human Services, where he served as chief technology officer and acting chief information officer. Prior to this, Simcox was director of US health care strategy, partnerships, and product development for AT&T. He also served as healthcare practice leader at Logicalis US, a global IT firm.

Feb 21, 2020

Predictive Oncology: Dan Handley

Predictive Oncology has appointed Dan Handley to its board of directors. Handley is a professor and director of the Clinical and Translational Genome Research Institute of Southern California University. Previously, he was chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida-based non-profit. He also previously served as chief scientific officer for Advanced Healthcare Technology Solutions; as a senior researcher at Procter & Gamble; a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine; and as a founding biotechnology inventor for the National Genetics Institute.

Feb 20, 2020

Sophia Genetics: Troy Cox

Sophia Genetics has named former Foundation Medicine CEO Troy Cox chairman of its board of directors, effective March 1. Cox will replace Antoine Duchateau, whom the company said will remain on the board. Cox, who also has held executive positions at US BioOncology and Genentech, joined the Sophia Genetics board in July 2019. 

Feb 19, 2020

Waters: Francis Kim

Francis Kim has resigned from his position as senior VP, global operations of Waters, effective March 16, 2020. He joined Waters in 2017 after 20 years at Medtronic, where he was VP of quality, Restorative Therapies Group.

Feb 18, 2020

Laboratory for Advanced Medicine: Benjamin Oyler

Laboratory for Advanced Medicine has appointed Benjamin Oyler as its chief operating officer. Oyler previously served as VP of strategy and business operations at Ancestry DNA and AncestryHealth. Prior to Ancestry, Oyler worked on several product launches, building operations, and manufacturing capabilities in the US and Asia. 

Feb 14, 2020

Biocept: Cory Dunn

Biocept has promoted Cory Dunn to Senior VP of commercial operations, succeeding Edwin Hendrick, who resigned to pursue other endeavors. Dunn previously served as Biocept's VP of commercial operations, beginning in October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix.  She holds an MA in education from Stanford University, and an MS in biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.

Feb 13, 2020

Sophia Genetics: Philippe Menu

Sophia Genetics has named Philippe Menu as chief medical officer. Menu joined the Swiss bioinformatics company from McKinsey, where he was co-leader of the McKinsey Cancer Center. A physician with a PhD in molecular biology, Menu primarily advised pharmaceutical and biotech companies in the development of new therapies and diagnostics in oncology and rare diseases. At Sophia, he will lead the firm's medical strategy.

Feb 13, 2020

Wamberg Genomic Advisers: Robert Green

Wamberg Genomic Advisers has appointed Robert Green to its advisory board. A medical geneticist and physician-scientist, Green directs the G2P Research Program in the Division of Genetics at Brigham and Women's Hospital and Harvard Medical School. He is principal investigator of the MedSeq project, an NIH-funded randomized trial to explore the use of whole-genome sequencing in the clinical practice of medicine, and co-leads the BabySeq project, evaluating sequencing in newborns.

Green also directs the recently established Brigham Preventive Genomics Clinic, which offers comprehensive genome sequencing and interpretation to healthy adults and their children. He was the lead author of the published recommendations from the American College of Medical Genetics and Genomics for management of incidental findings in clinical sequencing. As an advisor to Wamberg, Green will help guide the firm in its further development of product offerings and programs as well as lead the selection of future advisory board members from the scientific community. 

Feb 12, 2020

PreludeDx: Edwin Hendrick

PreludeDx has appointed Edwin Hendrick as the company's chief commercial officer. He has more than 30 years of related commercial experience and was most recently at Biocept. Before that, he was at Decipher Biosciences, formerly called GenomeDx, and at Plus Diagnostics. Laguna Hills, California-based PreludeDx's main product is the DCISionRT risk assessment test for patients with ductal carcinoma in situ

Feb 12, 2020

Decipher Biosciences: Robert Epstein, Kathy Hibbs

Decipher Biosciences has appointed Robert Epstein and Kathy Hibbs to its board of directors. Epstein was also elected as the firm's chairman.

Epstein is CEO and cofounder of Epstein Health. He also serves on the board of directors at Illumina, Fate Therapeutics, Veracyte, and Proteus Digital Health. Epstein previously served as president at Medco-UBC from 2010 to 2012. From 1997 to 2010, he held the role of Medco's chief medical officer. He has also served on the boards of directors of the Drug Information Association and the International Society of Quality of Life. In addition, he has served on the Centers for Disease Control and Prevention's Evaluation of Genomic Application in Practice & Prevention Stakeholder Committee, as well as on the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics Committee.

Hibbs has served as chief legal and regulatory officer for 23andMe since 2014. She has also served as a member of the Fast Company Impact Council since April 2019 and as a member of the board of directors of Cadex Genomics since Oct 2019. Prior to 23andMe, she was senior VP and general counsel at Genomic Health.

Feb 10, 2020

GenMark Diagnostics: Scott Mendel, Hany Massarany, Kevin O’Boyle, James Fox

GenMark Diagnostics has appointed Scott Mendel, its chief operating officer, as interim president and CEO, effective immediately. Hany Massarany has stepped down as president and CEO and as a member of the company’s board of directors, also effective immediately. GenMark said it has commenced a search to identify a permanent CEO.

The firm appointed Kevin O’Boyle as chairman of the board. James Fox, GenMark’s prior chairman, will remain on the board as a non-executive director.

Feb 07, 2020

Pacific Biosciences: Michael Phillips, Denis Zaccarin

Pacific Biosciences announced that Senior VP of R&D Michael Phillips will retire, effective April 1, 2020.

Phillips joined the company in 2005 and oversaw development of all sequencing systems, including the PacBio RS, launched in 2011; RS II, launched in 2013; Sequel, launched in 2015; and Sequel II, launched in 2019.

Denis Zaccarin, PacBio's VP of semiconductor integrated devices, will succeed Phillips as the head of R&D. Zaccarin, who holds a doctorate, joined the firm in 2004 and oversaw designs and development of SMRT cells.

Feb 06, 2020

Illumina: Scott Gottlieb

Illumina has appointed Scott Gottlieb to its board of directors. Gottlieb is currently a special partner at New Enterprises Associates and a resident fellow at the American Enterprise Institute. He previously served as the 23rd commissioner of the US Food and Drug Administration form 2017 to 2019. Prior to joining the US FDA as commissioner, Gottlieb was a clinical assistant professor at the New York University School of Medicine. 

Feb 05, 2020

Luna Genetics: Arthur Beaudet

Arthur Beaudet has retired from Baylor College of Medicine, where he was a professor of molecular and human genetics, molecular and cellular biology, and pediatrics. He is now full-time CEO of Luna Genetics, a startup he cofounded in 2018 that aims to develop fetal cell-based noninvasive prenatal tests.

Feb 05, 2020

Aperiomics: Elizabeth Pyle

Aperiomics has appointed Elizabeth Pyle as chief operating officer. Prior to joining Aperiomics, she directed the University of Virginia's National Sciences Entrepreneurship Program and founded consulting firm Pyle & Associates. Aperiomics leverages metagenomic sequencing and big data to identify every known bacteria, virus, fungus, and parasite. 

The New York City Police Department will be removing DNA profiles from a local database if they are from people who were never convicted of a crime, the New York Times reports.

Science reports that accusations of sexual assault against a microbiome researcher has also led to questions about his academic certifications.

Wired reports that researchers are analyzing the DNA fish leave behind in water to study their populations.

In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.